**Supplementary Table 1 Demographic and baseline characteristics of patients randomized to but excluded from the ABPM analysis set**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Placebo****(*n* = 32)** | **Mirabegron** **25 mg****(*n* = 32)** | **Mirabegron** **50 mg****(*n* = 29)** | **Solifenacin** **5 mg** **(*n* = 27)** | **Comb** **5+25 mg** **(*n* = 62)** | **Comb****5+50 mg****(*n* = 51)** |
| Age, mean (years) | 61.0 | 61.3 | 58.1 | 56.6 | 57.4 | 57.3 |
| Sex, female, *n* (%) | 24 (75.0) | 26 (81.3) | 23 (79.3) | 18 (66.7) | 45 (72.6) | 35 (68.6) |
| BMI (kg/m2), mean ± SD  | 29.1 ± 6.7 | 30.9 ± 8.0 | 30.3 ± 6.8 | 29.5 ± 6.8 | 29.8 ± 6.3 | 30.9 ± 6.1 |
| Hypertension, *n* (%) | 17 (53.1) | 18 (56.3) | 16 (55.2) | 10 (37.0) | 28 (45.2) | 24 (47.1) |

ABPM, ambulatory blood pressure monitoring; BMI, body mass index; Comb, combination solifenacin + mirabegron; SD, standard deviation.